325 related articles for article (PubMed ID: 32290519)
1. Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.
Yang Y; Liu X
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290519
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.
Yang Y; Li P; Zhang Z; Wang Z; Liu L; Liu X
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987693
[TBL] [Abstract][Full Text] [Related]
3. Transporter-Mediated Drug-Drug Interactions and Their Significance.
Liu X
Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective Drug Recognition by Drug Transporters.
Uwai Y
Molecules; 2018 Nov; 23(12):. PubMed ID: 30467304
[TBL] [Abstract][Full Text] [Related]
5. Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.
Zhou Q; Yu LS; Zeng S
Drug Metab Rev; 2014 Aug; 46(3):283-90. PubMed ID: 24796860
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
7. Transporters and drug-drug interactions: important determinants of drug disposition and effects.
König J; Müller F; Fromm MF
Pharmacol Rev; 2013 Jul; 65(3):944-66. PubMed ID: 23686349
[TBL] [Abstract][Full Text] [Related]
8. SLC Family Transporters.
Liu X
Adv Exp Med Biol; 2019; 1141():101-202. PubMed ID: 31571165
[TBL] [Abstract][Full Text] [Related]
9. A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.
Yang Y; Zhang Z; Li P; Kong W; Liu X; Liu L
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34064886
[TBL] [Abstract][Full Text] [Related]
10. Species differences in drug transporters and implications for translating preclinical findings to humans.
Chu X; Bleasby K; Evers R
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):237-52. PubMed ID: 23256482
[TBL] [Abstract][Full Text] [Related]
11. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
12. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.
Cheng Q; Aleksunes LM; Manautou JE; Cherrington NJ; Scheffer GL; Yamasaki H; Slitt AL
Mol Pharm; 2008; 5(1):77-91. PubMed ID: 18189363
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms Underlying the Differences in the Pharmacokinetics of Six Active Constituents of Huangqi Liuyi Decoction between Normal and Diabetic Nephropathy Mouse Models.
Wang Q; Wang Y; Liu W; Lu D; Jin Y; Tang N; Shi Y; Gong Z; Tian W; Liu T
Evid Based Complement Alternat Med; 2022; 2022():2481654. PubMed ID: 36285162
[TBL] [Abstract][Full Text] [Related]
14. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
15.
Zhou S; Shu Y
Drug Metab Dispos; 2022 May; 50(9):1238-50. PubMed ID: 35644529
[TBL] [Abstract][Full Text] [Related]
16. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
Bucher S; Le Vee M; Jouan E; Fardel O
J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
[TBL] [Abstract][Full Text] [Related]
17. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
18. Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol.
Li Y; Lu L; Wang L; Qu W; Liu W; Xie Y; Zheng H; Wang Y; Qi X; Hu M; Zhu L; Liu Z
Mol Pharm; 2018 Dec; 15(12):5602-5614. PubMed ID: 30376625
[TBL] [Abstract][Full Text] [Related]
19. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
20. Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F; Zhu L; Wang K; Murray M
Adv Drug Deliv Rev; 2017 Jul; 116():21-36. PubMed ID: 27320645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
